Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency

Bavarian Nordic's Share Price Increase:
The company's shares jumped over 12% in Danish trading after announcing a quarterly revenue beat and a significant contract to supply 440,000 doses of smallpox and mpox vaccine to an undisclosed European country.

Revenue and Earnings:
Bavarian Nordic reported second-quarter revenue of 1.43 billion Danish kroner ($212.9 million), exceeding analysts' consensus estimates, and an operating profit of 420 million kroner.

WHO Declaration:
The World Health Organization (WHO) declared the mpox outbreak in Africa a global health emergency due to a surge in cases in the Democratic Republic of Congo and neighboring countries.

Vaccine Production Capacity:
The company has the capacity to produce about 10 million doses of the mpox vaccine by the end of next year and expects to deliver up to 2 million doses this year.

Global Response:
The WHO and other health organizations are scaling up efforts to support countries in curbing the mpox outbreak, emphasizing the need for enhanced preparedness and international coordination.